function are complex and have been proposed to include activation of AKT (49) , upregulation of HIF1-α (50) , and increased VEGF (50) and MMP-2 secretion (51) . Overlapping roles have been proposed for PLD2 (52) . Small molecule inhibitors of PLD1 and PLD2 such as FIPI (53) or isoform-selective analogs (20) have been shown to have dramatic effects on human glioma cell lines in tissue culture studies in the context of the PLD-driven roles above. How useful suppression of PLD activity will be for management of gliomas in vivo though remains to be determined.
PLD1 and Fibrosis
PLD1 has been speculated to participate in the process of fibrogenesis in multiple tissue types including liver (54, 55) , lung (56) , and the heart (57, 58) . PLD1 is known to be directly connected to autophagy (59, 60) , the self-degradative process required for cellular homeostasis that is linked to several forms of liver diseases (61) (62) (63) . Based on recent reports, cardiac fibrosis is of particular interest.
PLD mRNA, protein, and activity levels decrease during congestive heart failure subsequent to myocardial infarction in the scar tissue (57) . The importance of this observation is suggested by a report that inhibition of PLD activity markedly attenuates left ventricular fibrosis, resulting in subsequent improvement in cardiac function (64) . PLD would thus seem to be an attractive therapeutic target for scar remodeling and reducing left ventricular fibrosis. On the other hand though, PLD1 deficiency, which blunts immune responses (65) , hinders immune-driven elements of the repair process after myocardial infarction (38) . Thus, there may be a balance between too little and too much PLD1 activity in this setting or specific sites at which PLD1 expression is harmful or beneficial. Similarly, there may be specific times during the repair process when PLD1 elevation is either helpful or harmful.
Phospholipase D2
Roles for PLD2 in thrombotic disease (37, 66) , cancer (67, 68), Alzheimer's disease (69) and immune function (65) based on animal model studies have recently been summarized (5) . Other potential functions have been raised by tissue culture studies, some of which will be reviewed here.
PLD2 and Influenza
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Influenza epidemics and reoccurring pandemics continue to pose a great threat to public health worldwide, in part due to the viruses' high mutation and replication rates (70, 71) . As a consequence, treatment and prevention measures for influenza virus infections remain challenging. For example, in this current flu season, for which the immunization cocktail was largely ineffective through being directed at the incorrect strains, the anti-influenza therapeutic amantadine was also found to be of relatively little benefit due to extensive acquired viral resistance to it (72) , suggesting the need for new therapeutic approaches. A genome-wide RNA interference (RNAi) screen identified 287 human host cell genes that influence the viruses' ability to replicate, of which 29 were required for all of the viral strains tested (73) . Among these, PLD2 was identified as a targetable candidate (73) . A subsequent study using an isoform-selective PLD2 inhibitor further supported a critical role in the viral replication process: PLD2 was found to mediate rapid endocytosis of the virus, facilitating its escape from innate immune detection (74) . As PLD2 knockout mice are grossly normal to inspection (69) , PLD2 would appear to fit the category of a "temporarily dispensable host gene" that could be acutely targeted to suppress viral replication. One caution for this approach would entail potential effects of PLD2 inhibition on the immune system, which were previously reported to decrease macrophage phagocytosis and neutrophil migration (65) . However, this might not be a substantive issue if the effects on the immune response to influenza were limited whereas the effects on viral replication are profound.
PLD2 and Cancer
PLD2 polymorphisms, as well as up-regulated protein activity levels have been observed in several types of cancer including gastric, colorectal, kidney and breast (68, (75) (76) (77) . In a particularly interesting recent report, it was observed that expression of microRNA (miR)-203 in high WHO grade glioma tissues was significantly lower than in low WHO grade gliomas and normal brain tissue. Transfection of a miR-203 mimic into human glioma cells strongly and directly downregulated PLD2 expression and in parallel suppressed proliferation and invasion of the glioma cells, whereas PLD2 overexpression rescued the effects induced by the miR-203 mimic. Taken together, these observations suggest important causal roles for PLD2 in glioma proliferation and invasive capacity (52) . In a human breast cancer xenograft model, it was shown that increased PLD2 expression in tumor cells suppresses by guest, on September 21, 2017 www.jlr.org Downloaded from apoptosis, ultimately facilitating tumor growth and chemoresistance (68) . PLD2 may also play roles in the tumor environment similar to those previously reported for PLD1 (39) , since PLD2 ablation from endothelial cells suppresses their hypoxia-induced Hif1-α expression and VEGF secretion, reducing proximal tumor neovascularization and growth (67) . Although the overall expression levels of PLD2 may vary in tumors, there is a significant correlation between PLD2 expression level and tumor size (p<0.05) as well as with survival of patients with colorectal carcinoma (p<0.05) (78) .
Immunohistochemical staining of 30 human colon cancer samples revealed a high level of correlation between Hif1-α and PLD2 (79) . Moreover, Hif1-α and PLD2 expression levels are much higher in colon cancer tissues than in normal colon tissues (p<0.01) (79) , and under hypoxic conditions, Hif1-α upregulates PLD2 expression in colon cancer cells (79) . Similar to PLD1, PLD2 should also be viewed as a major therapeutic target in the treatment of several forms of cancer.
Phospholipase D3
PLD3 and Alzheimer's disease PLD1, PLD2 and PLD3 have all been implicated in Alzheimer's disease (AD) (69, 80, 81) . PLD3 is highly expressed in the brain, including in but not limited to mature neurons of the forebrain, the hippocampus and cortex (81) (82) (83) . Rare coding variants in PLD3 have been associated with up to 9% of late-onset AD in 14 families of European ancestry (81) (Fig. 3) . More specifically, Val232Met, a putative loss-of-function polymorphism, is proposed to increase pathogenic amyloid peptide (Aβ) secretion and hence increase the risk for late-onset AD (81) . This increased risk is independent of the APOE genotype (81) . Similarly, PLD3 putative loss-of-function polymorphisms have been reported to correlate with increased risk of AD in African-Americans (81) . Independent of the coding variants, PLD3 protein expression is down-regulated in AD brains (84) and in cortical membrane lipid rafts prepared from the 3xTgAD murine model of AD (85) .
The mechanism of action of PLD3, as well as whether or not it encodes any type of catalytic activity, remains unknown, but its placement in the ER and secretory system suggests how it might suppress Aβ secretion. AβPP, the precursor protein to Aβ, is proteolytically processed to generate Aβ in early endosomes, and the extent of this processing depends on how rapidly it is trafficked from the early endosome to late endosomes and lysosomes. Key to this process is the phosphatidylinositol-3-phosphate effector Hrs, an early endosome-associated ubiquitin-interacting motif (UIM)-containing protein that plays a central role in directing trafficking of membrane cargo proteins from early endosomes to luminal vesicles of multivesicular bodies (MVBs) for eventual degradation in the lysosome. Knock-down of Hrs or other proteins required for the transport of AßPP from early endosomes to luminal vesicles of MVBs results in increased amyloidogenic processing (86) , supporting the general hypothesis that any defect that keeps AßPP and its processing enzyme BACE1 in endosomes will increase Aβ production and drive pathology (87) . Intriguingly, a recent screen for ubiquitinated proteins specifically recognized by Hrs identified 48 targets, among which were AßPP and PLD3 (88) .
PLD3 has been reported in secretory granules in an insulin-producing pancreatic β-cell line (89) and in a pattern partially overlapping with lysosomes in HeLa cells (90) , suggesting that PLD3 protein may traffic through endosomal pathways, even if the most abundantly observed steady-state location is in the ER in cultured cell lines (29, 32) . PLD3 has been identified in multiple screens for proteins that become ubiquitinated (88, (91) (92) (93) . One site for PLD3 ubiquitination is its short cytoplasmic N-terminal domain, K11 (Fig. 3) . This key finding suggests that PLD3 undergoes cytoplasmic ubiquitination and could be recognized and sorted by Hrs to co-traffic with AßPP from endosomes to luminal vesicles of MVBs. Supporting this hypothesis, a PLD3 allele with significant association with late-onset AD, in which methionine 6 is substituted for by arginine (M6R), occurs in an amino acid residue close to K11 and could potentially affect ubiquitination, providing a basis for its disease linkage. These data, taken together, suggest that if ubiquitinated, Hrs-trafficked PLD3 plays a role in moving AßPP from early endosomes to luminal vesicles of MVBs for eventual lysosomal degradation, then a decrease in or a lack of ubiquitination, as well as non-functional PLD3, could cause AßPP retention in early endosomes and increased Aß production to promote AD pathology.
Independently, a screen performed for targets of the FBOX6 ubiquitin ligase complex, which triggers endoplasmic reticulum-associated degradation (ERAD) by mediating glycoprotein by guest, on September 21, 2017 www.jlr.org Downloaded from ubiquitination, identified 29 targets including PLD3 (92) . The ERAD system functions by recognizing improperly folded glycoproteins and poly-ubiquitinating and transferring them to the cytosol to be degraded by proteasomes. The second PLD3 site that becomes ubiquitinated is in the C-terminal ERluminal portion of the protein (K309, Fig. 3 ) (91) and would be a candidate target site for this mechanism. A report on PLD3 in late-onset AD (81) identified six disease-associated alleles that are predicted by Polyphen-2 (94) to be possibly or probably damaging and are located in or near putative glycosylation sites (Fig. 3) . If these mis-sense mutations cause altered glycosylation or misfolding, then the ERAD system might target the PLD3 protein for degradation, causing a significant decrease in protein expression levels.
It is notable that none of the alleles identified encoded nonsense mutations (premature stop codons), suggesting that full or even heterozygous PLD3 loss might be deleterious. PLD3
-/-mice have not been generated yet. A drosophila line with a P element insertion into its PLD3 homolog does exist and is embryonic lethal when homozygous (unpublished). However, this line could have other genetic abnormalities or the P element could be affecting expression of other nearby genes, so additional studies would need to be performed to conclude that PLD3 loss creates lethality.
Finally, other groups have reported variable success in reproducing the genetic association of PLD3 polymorphisms with late-onset AD (95) (96) (97) , suggesting that the linkage may be less robust than initially projected.
Phospholipase D4

PLD4 and Autoimmune Diseases
As is the case for PLD3, it is not known whether PLD4 has a bona fide enzymatic function.
Nonetheless, PLD4 clearly has important functional roles. Initial reports described PLD4 expression in microglia, the macrophage-like innate immune cells of the CNS, as well as in splenic cells, presumably macrophages. PLD4 expression increases with microglial activation, which is also characterized by increased phagocytic capacity (34, 98) . siRNA knockdown of PLD4 suppressed phagocytosis, suggesting a role for PLD4 in the setting of CNS injury and infection (34, 98) . A nonsense mutation in PLD4 (W215X) in Fleckvieh cattle causes severe skin lesions, generally poor health, and decreased survival (99) . PLD4 deficiency in humans has been linked through genome-wide association studies to syndromes such as rheumatoid arthritis (RA) (100) and the autoimmune disease systemic sclerosis (101) . Taken together, these findings suggest that PLD4 deficiency results in hyper-activation of the immune system, causing a variety of autoimmune-like syndromes.
Phospholipase D5
PLD5 and Uterine Fibroids
Despite having no catalytic activity, PLD5 has been linked to a number of diseases, including a profibrotic uterine phenotype that occurs during childbearing years, and PLD5 polymorphisms may be associated with an increased risk of tumor progression in multiple cutaneous and uterine leiomyomatosis syndrome (102).
PLD5 is most widely known for its correlation with neuropsychiatric disorders. Autism, the neurological disorder associated with impaired social relationships and communication as well as repetitive behavior, is predominantly linked to de novo and inherited copy number variants of genes important for neuronal development (103) (104) (105) . High-resolution genotyping of 1558 families on the autism spectrum uncovered a PLD5 gene polymorphism as possibly being connected with autism physiopathology (106) . Although the association signal of this SNP was borderline significant, further investigation is warranted, since autism has been proposed to be caused primarily by multigene interactions rather than solely by single rare mutations.
Phospholipase D6 (MitoPLD)
PLD6-deficient mice, which cannot generate piRNAs to suppress transposon mobilization during spermatogenesis, are completely sterile (15) , but are otherwise grossly normal to inspection. PLD6 mutations do not appear to be a major cause of human infertility; sequencing of PLD6 in 400 azoospermic European men did not uncover any PLD6 polymorphisms (unpublished observation).
Nonetheless, PLD6 may have other, less obvious roles. This past year, PLD6 was identified as a predictive biomarker for regression of CIN2+ to CIN1 (108).
PLD6 was expressed in 12 out of 20 cervical punch biopsy samples taken from women 25-40 years old who experienced spontaneous regression, whereas no PLD6 expression was found in any of the biopsy samples from women whose CIN2+ progressed to cervical cancer (108) . piRNAs can be recovered from the human HeLa cervical cancer cell line, suggesting that the machinery to generate piRNAs is functional in cervical tissue (115) . Adding PLD6 to the list of biomarkers for CIN2+ cervical lesions should further increase sensitivity in determining whether a patient's cervical intraepithelial neoplasia will spontaneously regress or persist and develop into cervical cancer.
Concluding Remarks
With many of the PLD-deficiency animal models recently generated, the field is in an explosive period of discovery for roles undertaken by this fascinating superfamily of enzymes. Some of the associated pathophysiological roles reflect undesirable PLD activity, whereas others occur as a consequence of inadequate activity ( 
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